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CHAPTER 1 - INTRODUCTION 
The SUMOylation pathway 
             Small ubiquitin-related modifier proteins (SUMOs) contain approximately 100 amino 
acids and are covalently attached to hundreds of different proteins in eukaryotic cells.  
SUMOylation is an essential posttranslational modification in eukaryotes and regulates a wide 
range of biological processes, including cell cycle progression, DNA repair, gene expression, 
nucleocytoplasmic transport, protein degradation/stability, and stress response (Pichler and 
Melchoir, 2002; Johnson, 2004).  Three different SUMO isoforms, including SUMO-1, SUMO-2 
and SUMO-3, are expressed in mammals, whereas only one SUMO called Smt3 is expressed in 
budding yeast.  The human SUMO-2 and SUMO-3 are about 95% identical to each other and 
therefore referred to as SUMO-2/3, whereas they share only 45% identity to SUMO-1.  The N-
terminal extension of SUMO-2/3 acts as a site for the formation of polymeric SUMO-2/3 chains.   
           The enzymatic cascade of SUMOylation is similar to that of ubiquitination.  In eukaryotic 
cells, SUMO is expressed as a precursor protein whose C-terminal region needs to be processed 
by a family of SUMO-specific isopeptidases to expose its double glycine motif, leading to the 
generation of mature SUMO (Figure 1).  This mature SUMO is then activated by a SUMO-E1 
activating enzyme (SAE1/SAE2, also known as Aos1/Uba2) by forming a thioester bond 
between the catalytic cysteine of Uba2 and the C-terminal glycine of SUMO.  This is followed 
by the transfer of SUMO from the E1 to the sole SUMO-E2 conjugating enzyme (Ubc9), leading 
to the formation of a thioester bond between the catalytic cysteine of Ubc9 and the C-terminal 
glycine of SUMO (Friedlander and Melchoir, 2007).  Subsequently, the charged Ubc9 
recognizes the SUMOylation consensus motif ΨKxD/E (Ψ represents a hydrophobic amino acid 
residue, K is a lysine residue, x can be any amino acid residue, and D/E represents aspartic acid 
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or glutamic acid) which are present in many SUMO targets (Villamor et al., 2002; Tatham et al., 
2003). SUMO is then transferred from the charged Ubc9 to the substrate by forming an 
isopeptide bond between the C-terminal glycine of SUMO and the lysine residue of the target 
protein (Johnson, 2004). Several E3 ligases, including different PIAS family proteins and 
Nup358/RanBP2, facilitate the transfer of SUMO from Ubc9 to the target proteins.  As a 
reversible process of SUMOylation, SUMO is deconjugated from its target by a family of 
SUMO-specific isopeptidases, including SENP1, SENP2, SENP3, SENP5, SENP6, SENP7, 
DeSI-1, DeSI-2, and USPL1 in mammals.  However, only two SUMO-specific isopeptidases 
called Ulp1 and Ulp2 have been identified in budding yeast (Hickey et al., 2012). 
            Interestingly, all the protein components essential for SUMOylation, including SUMO E1 
and E2 (Ubc9) enzymes as well as SUMO-1 and SUMO-2/3, are mainly localized in the nucleus 
in vertebrate cells (Azuma et al., 2001; Saitoh et al., 2001; Lee et al., 1998; Zhang et al., 2002).  
In HeLa cells, SUMO E1 enzyme (Aos1/Uba2) is primarily nuclear (Azuma et al., 2001), 
whereas Ubc9 is predominantly localized in the nucleus as well as at the nuclear pore complex 
(Saitoh et al., 2001; Lee et al., 1998; Zhang et al., 2002) (Figure 2).  In addition, both SUMO-1 
and SUMO-2/3 are majorly concentrated in the nucleus under immunofluorescence microscopy 
using antibodies specific to SUMO-1 and SUMO-2/3 respectively (Zhang et al., 2008) (Figure 
2). These observations are consistent with the observations that most of the SUMOylated 
substrates are nuclear proteins.  It has been hypothesized that SUMO-modification 
predominantly occurs in the nucleus and thus the nuclear localization of SUMO E1 and E2 
enzymes in the nucleus is critical for efficient SUMOylation.  Consistent with this hypothesis, it 
has been shown recently that the inhibition of Ubc9 nuclear localization in cells expressing a 
mutant form of lamin A responsible for the premature aging disease called Hutchinson-Gilford 
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progeria syndrome is correlated with a decrease of SUMO-2/3 modification in the nucleus (Kelly 
et al., 2011).  Furthermore, the artificial fusion of the SUMOylation consensus motif to Pyruvate 
Kinase (PK), a cytoplasmic protein, has been found to be efficient for its SUMOylation in vitro, 
yet its modification in vivo requires the additional presence of a nuclear localization signal (NLS) 
for its nuclear localization, suggesting that most SUMO substrates need to be imported into the 
nucleus for their sufficient sumoylation (Rodriguez et al., 2001).   
 
Figure 1. The SUMO pathway. The SUMO precursor is processed by SUMO isopeptidases 
(SENPs) in vertebrates to expose its C-terminal double-glycine (GG) motif.  The mature SUMO 
is activated by the E1 activating enzyme to form a thioester bond between the C-terminal glycine 
of SUMO and the catalytic cysteine (C) of the E1.  SUMO is then transferred to the catalytic 
cysteine (C) of the E2 conjugating enzyme Ubc9.  Finally, SUMO is transferred from Ubc9 to a 
substrate by forming an isopeptide bond between SUMO and a lysine (K) of the substrate.  The 
last step is often facilitated by an E3 ligase. SUMO is deconjugated by SENP isopeptidases. This 
figure is adapted from Wan et al., 2012. 
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Figure 2. The essential components of SUMOylation machinery are concentrated in the 
nucleus. (A) The only SUMO E1 enzyme (Aos1/ Uba2) is primarily localized in the nucleus in 
HeLa cells (Azuma et al., 2001). (B) The sole SUMO E2 enzyme (Ubc9) is predominantly 
accumulated in the nucleus (Saitoh et al., 2001). (C) Both SUMO-1 and SUMO-2/3 are majorly 
concentrated in the nucleus (Zhang et al., 2008). 
           The sole SUMO-E1 activating enzyme consists of two subunits, Aos1 and Uba2, and is 
known to be imported from the cytoplasm to the nucleus by Importin α/β.  Importin α can bind to 
each of the E1 subunits either individually or to the Uba2 subunit in the cytoplasm and actively 
transports them to the nucleus (Moutty et al., 2011). However, the mechanism underlying the 
nuclear localization of Ubc9 is still unclear. In vitro study has shown that Importin 13 (Imp13), 
one of the members of the karyopherin β family, translocates Ubc9 from the cytoplasm to the 
nucleus (Mingot et al., 2001). In this study, in vitro nuclear import assays were performed using 
fluorescently labeled recombinant Ubc9.  Different importin receptors, including Impα/β, Imp5, 
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Imp7, Imp13 and transportin, were respectively added to the permeabilized cells in the presence 
of Ran and ATP as the energy source.  The nuclear import of Ubc9 was stimulated only by 
Imp13, and this Imp13-Ubc9 interaction was disrupted in the presence of RanGTP in vitro, 
indicating that Ubc9 is released from the import complex by the high concentration of RanGTP 
in the nucleus (Mingot et al., 2001).  
            As the only SUMO-E2 enzyme, Ubc9 plays an essential role in SUMOylation and thus 
regulates many critical cellular processes.  In yeast, Ubc9 is required for cell cycle progression 
through mitosis as its deletion causes the cells to arrest at G2/M phase (Seufert et al., 1995). 
Ubc9 has been implicated in tumorigenesis since Ubc9 is upregulated in various types of human 
cancer, including ovarian and lung cancers, as compared to the corresponding normal control 
samples (Mo et al., 2005; Li et al., 2013).  Upregulation of Ubc9 expression has been found to 
promote the migration, invasion and metastasis of lung cancer cells (Li et al., 2013).  Ubc9 forms 
a complex at the nuclear pore complex with proteins including SUMO-1 modified RanGAP1 and 
Nup358/RanBP2 (Zhang et al., 2002). One of the interesting feature of Ubc9 is that it can also be 
SUMOylated, leading to the formation of SUMO-modified Ubc9 (Ubc9*SUMO). The SUMO 
modification site of Ubc9 in mammals and budding yeast is Lys14 and Lys153 respectively. The 
SUMOylated form of Ubc9 governs several functions. In mammalian cell, SUMOylation of 
Ubc9 can alter its target specificity by repressing RanGAP1 modification but activating 
SUMOylation of a transcriptional regulator called Sp100 (Knipscheer et al., 2008).  In budding 
yeast, a SUMOylation-deficient mutant of Ubc9 exhibits a defect in synaptonemal complex 
formation during meiosis (Klug et al., 2013).  
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Figure 3. Non-covalent interactions between Ubc9 and SUMO. Picture shows amino acid 
residues of Ubc9 that are involved in Ubc9 interaction with SUMO. R13, R17 and H20 are 
critical sites on Ubc9 which are crucial for Ubc9-SUMO complex formation (Knipscheer et al., 
2007). 
During the process of SUMO-conjugation, Ubc9 is known to interact with the E1 
enzyme, SUMO, a SUMO-E3 ligase, and a protein substrate.  Structural studies in combination 
with mutational and biochemical analyses have demonstrated that Ubc9 directly interacts with 
the SUMOylation consensus motif (ΨKxD/E) on SUMO substrates.  Ubc9 can also form a 
complex with a Nup358/RanBP2, a SUMO E3 enzyme, and also the SUMO-1-modified 
RanGAP1 at the nuclear pore complex (NPC) (Reverter and Lima, 2005; Matunis et al., 1996).  
The residues that are crucial for Ubc9 binding to the substrate and also required for SUMO-
modification have been identified previously (Bernier-Villamor et al., 2002).  As shown in 
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Figure 3, multiple amino acid residues of Ubc9 are critical for its interaction with SUMO.  
Several Ubc9 mutants such as R17E, R13A and H20D are deficient in forming a complex with 
SUMO.  Biochemical analyses revealed that the Ubc9-R17E and Ubc9-R13A mutants with a 
defect in SUMO-binding also have defects in the formation of Ubc9~SUMO thioester bond as 
well as the assembly of free poly-SUMO chain in vitro.  On the other hand, the Ubc9-H20D 
mutant with a defect in SUMO-binding doesn’t show a deficiency in the formation of thioester 
bond between Ubc9 and SUMO (Ubc9~SUMO) (Tatham et al., 2003; Capili and Lima, 2007; 
Knipscheer et al., 2007).  These studies suggest that the non-covalent interaction of Ubc9 with 
SUMO and/or the SUMO-consensus motifs of nuclear proteins might be crucial for Ubc9 
nuclear localization.  
Nucleocytoplasmic transport 
             NPCs are the gates at nuclear envelope for transport of macromolecules between the 
cytoplasm and the nucleus. Passive diffusion through NPCs is a common mode of transport for 
molecules with sizes up to ~20-40 kDa, while other larger molecules require active transport to 
pass through the NPCs (Gorlich and Kutay, 1999; Mohr et al., 2009). This active transport of 
cargoes is mainly facilitated by a family of nuclear transport receptors called karyopherin-β 
which are broadly classified into two categories including importins and exportins.  Importin 
binds the nuclear localization signal (NLS) of an import cargo in the cytoplasm and then 
translocates it into the nucleus, where the cargo is released from the importin-cargo complex 
upon RanGTP binding (Rexach and Blobel, 1995; Pemberton and Paschal, 2005).  On the other 
hand, exportin forms the exportin-RanGTP-cargo complex in the nucleus, translocates through 
the NPC, and releases its cargo in the cytoplasm when RanGTP is hydrolyzed to RanGDP (Cook 
and Conti, 2010).  Both nuclear import and export cycles are illustrated in Figure 4. 
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Figure 4. A diagram for nuclear import and export. In nuclear import, cargo binds to the 
import receptor in the cytoplasm and translocates to the nucleus where upon RanGTP binding, 
cargo is released from the import receptor. In the export pathway, cargo, RanGTP and export 
receptor forms a ternary complex in the nucleus. RanGTP hydrolysis in the cytoplasm, leads to 
the release of cargo from the export receptor (Adapted from Molecular Biology of the Cell, Fifth 
Edition, Alberts). 
A few karyopherins such as Imp13, Msn5 and Exportin 4 have been identified as a 
bidirectional transport receptors that can both import and export cargoes in and out of the 
nucleus, respectively (Mingot et al., 2001; Yoshida and Blobel, 2001; Gontan et al., 2009).  One 
of the directions that my study has focused on is Imp13-mediated nuclear import of Ubc9. 
Imp13: Bi-directional transport receptor 
           Several studies have shown that Imp13 mediates both nuclear import and export of 
multiple cargoes.  In addition to Ubc9 as the first identified import cargo of Imp13 (Mingot et 
al., 2001), the other Imp13 import cargoes include the paired-type homeodomain transcription 
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factors (Pax6, Pax3 and Crx) (Ploski et al., 2004), glucocorticoid receptor (Tao et al., 2006), the 
actin bundling protein called myopodin (Liang et al., 2008),  two histone fold heterodimeric 
proteins (CHRAC-15/CHRAC-17 and p12/CHRAC-17) (Walker et al., 2009), and the core 
components of exon junction complex (EJC) including Mago and Y14 (Bono et al., 2010) in 
mammalian cells.  So far, the eukaryotic translation initiation factor called eIF1A is the only 
known export cargo of Imp13 (Mingot et al., 2001). 
           Apart from being a bi-directional transport receptor, Imp13 has been identified as a 
potential marker for corneal epithelial progenitor cells (Wang et al., 2009). Furthermore, recent 
studies have shown that Imp13 is significantly upregulated in endometriosis and endometrial 
carcinoma when compared to secretory phase endometrium and can be used as an endometrial 
progenitor/stem cell marker (Zeng et al, 2012). Moreover, Imp13 is highly expressed in the 
epithelial cells of pterygium and plays a critical role in enhancing cell proliferation (Xu et al., 
2013).  By analyzing the expression of Imp13 among different stages of embryonic and adult 
brain tissues, levels of Imp13 mRNAs and proteins were consistently decreased during mouse 
brain development (You et al., 2013).  Intriguingly, Imp13 localized in the cytoplasm at the early 
stages and then accumulated in the nucleus at the late stages of brain development (You et al., 
2013). 
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Figure 5. Imp13 mediated nuclear import of Ubc9 in vitro. Fluorescently labeled recombinant 
GST-Ubc9 with different nuclear transport receptors in the presence of Ran and energy were 
imported to HeLa cells permeabilized with digitonin. Only Imp13 could mediate nuclear 
accumulation of Ubc9. This nuclear import was dependent on Ran and ATP (Mingot et al., 
2001). 
            As previously mentioned, Ubc9 nuclear import is mediated by Imp13 in vitro (Mingot et 
al., 2001). In this study, a nuclear import assay was performed where fluorescently labeled GST 
tagged Ubc9 was used. Cells were permeabilized with digitonin and then incubated with 
different importins including Impα/β, Imp5, Imp7, Imp13 and transportin respectively in the 
presence of Ran GTPase and ATP. As shown in Figure 5, only Imp13 facilitated the transport of 
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Ubc9 to the nucleus.  Structural study of the Imp13-Ubc9 complex has revealed that Ubc9 binds 
to the N-terminus of Imp13 (Grünwald and Bono, 2011). In vitro binding assay indicated that the 
interaction between Ubc9 and Imp13 was disrupted when the R17 residue on Ubc9 was mutated 
to E or when the D426 residue on Imp13 was mutated to R. This study revealed the residues on 
both Imp13 and Ubc9 that are critical for their interaction (Grünwald and Bono, 2011).      
          Although in vitro nuclear import assays have revealed that Imp13 can mediate nuclear 
import of Ubc9, little is known about whether Imp13 is the major nuclear import receptor for 
Ubc9 and whether Imp13-mediated nuclear import of Ubc9 is important for efficient 
SUMOylation in vivo.  In this study, we investigated how the nuclear localization of Ubc9 is 
regulated in mammalian cells and also addressed the functional significance of Ubc9 nuclear 
localization in control of efficient SUMOylation in vivo.  We first focused on Imp13-mediated 
nuclear import of Ubc9 in regulation of Ubc9 nuclear localization and also the efficient 
SUMOylation in vivo. We then tested whether the non-covalent interaction between Ubc9 and 
SUMO also plays a role in control of Ubc9 nuclear distribution. 
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CHAPTER 2 - METHODS 
Cell culture and transfection 
            HeLa cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM; HyClone) 
supplemented with 10% Fetal Bovine Serum (FBS) and 1% Pencillin-Streptomycin (Invitrogen) 
and cultured at 37
o
C with 5% CO2.  Cells were transfected with the indicated plasmids using 
Lipofectamine and Plus reagents (Invitrogen) following the manufacturer’s protocols.  The 
transfected cells were analyzed by Western blot and/or immunofluorescence microscopy. 
Immunofluorescence microscopy 
           HeLa cells were grown on coverslips in 6-well plates. After 24-48 h of transfection, cells 
were washed twice with 1xPBS (137 mM NaCl, 2.7 mM KCl, 1.5mM KH2PO4, 8.1 mM 
Na2HPO4, pH 7.36) fixed with 3.5% paraformaldehyde in 1xPBS for 30 min. Cells were then 
permeabilized with ice-cold acetone for 5 min, incubated with rabbit anti-HA primary antibody 
(Santa Cruz) (1:50 dilution in 1xPBS containing 2%BSA and 0.02% sodium azide) for 1 h 
followed by washing with 1xPBS for three times. Cells were further incubated with Alexa Fluor 
594-conjugated goat anti-rabbit IgG secondary antibody (Invitrogen) (1:200 dilution) for 30 min 
at room temperature (RT) and then washed three times with 1xPBS.  The coverslips with cell 
side down were slowly placed onto the mounting solution (100 mM Tris pH8.8, 50% Glycerol, 
2.5% DABCO and 0.2 μg/ml DAPI for DNA staining) on the microscope glass slide, incubated 
for 3-5 min, and then sealed with colorless nail polisher.  Images were collected using Olympus 
inverted IX81 fluorescence microscope. 
Plasmid constructs 
           Mammalian Imp13 vector (pCMV-SPORT6) was purchased from Invitrogen. Complete 
ORF was subcloned into pEGFP-C1 vector between Xho I and BamH I sites. The Imp13 
13 
 
 
 
fragment (1-488 amino acids) was subcloned between BamH I and Xho I sites in pGEX-4T-1 
vector.  The mouse C-terminal HA-tagged Imp13 was obtained from Dr. Tao Tao (Tao et al., 
2006).  The Ubc9-WT (wild type) and Ubc9-R17E mutant were subcloned into pEGFP-C1 
vector between EcoR I and BamH I sites.  For protein expression and purification, Ubc9-WT or 
Ubc9-R17E was subcloned into pGEX-6P-1 vector between BamH I and Xho I restriction sites.  
All clones were verified by restriction digestions and DNA sequencing. Primers for PCR 
amplifications and subclonings are listed in Appendix A. 
Site-directed mutagenesis 
           Ubc9 and Imp13 mutants were generated using site-directed mutagenesis. To generate the 
Ubc9-R17E mutant, the arginine (R) 17 residue of human Ubc9 was mutated to glutamic acid 
(E).  To study the non-covalent interaction between Ubc9 and SUMO, the arginine 13 of Ubc9 
was mutated to alanine for the generation of the Ubc9-R13A mutant, whereas the histidine 20 
was mutated to aspartic acid for generating the Ubc9-H20D mutant.  To generate the mouse 
Imp13-D426R mutant with a defect in Ubc9 interaction, the aspartic acid (D) 426 of Imp13 was 
mutated to R. The PCR amplifications were performed using Pfu Turbo DNA polymerase 
(Agilent) and the corresponding mutagenesis primers listed in Appendix B.  The PCR products 
were treated with 1 μl of Dpn I restriction enzyme (NEB) for 1 h at 37o C and transformed to 
XL1-Blue electro-competent cells (lab made).  The transformed cells were plated on Luria 
Bertani (LB) plates containing the respective antibiotics.  
Protein expression and purification 
          The GST-tagged human Imp13 and Ubc9 were expressed in E.coli strain BL21.  The 
expression of GST-Imp13 was induced with 0.5 mM IPTG at 18
o
C overnight.  Induction of 
GST-Ubc9-WT, GST-Ubc9-R17E and GST were carried out for 4 h at 37
o
C with 1 mM IPTG. 
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After induction, cells were lysed in 1x Lysis buffer comprising of 25 units/ μl Benzonase, 0.2% 
TritonX-100, 1 mg/ml Lysozyme, and protease inhibitors (including 5 μg/ml LAP (Leupeptin, 
Antipain and Pepstatin), 1 mM PMSF and 20 μg/ml Aprotonin) in1x PBS.  The GST or GST-
tagged proteins were then bound to the Glutathione Sepharose beads (GE Healthcare). 
The GST tag of GST-Ubc9 was cleaved using GST-tagged PreScission Protease. The 
GST-tagged Ubc9 fusion proteins were first bound to the glutathione sepharose beads and then 
incubated with the PreScission Protease at 4
o
C overnight.  The supernatant containing the 
untagged Ubc9 was collected and then used for in vitro Imp13-Ubc9 binding assays.  All the 
protein concentrations were measured using Bradford protein assays (Bio-Rad). The purified 
proteins were also analyzed using Commassie Blue staining and immunoblot analyses.   
In vitro binding assays 
            To characterize the interaction between Imp13 and Ubc9, 24 μg of GST-Imp13 and 10 μg 
of GST alone were immobilized to the glutathione sepharose beads (GE Healthcare), 
respectively, and then blocked with 200 μl of Binding buffer (20mM HEPES pH 7.5, 50 mM 
NaCl, 1 mM DTT, 10% glycerol, and 0.01% NP-40) containing 2% BSA and 0.02% Sodium 
Azide for 30 min at 4
o
C.  After blocking, the beads were washed twice with Binding Buffer. 5 μg 
of Ubc9-WT or Ubc9-R17E were incubated with the beads immobilized with either GST-Imp13 
or GST for 2 h at 4
o
C.  The beads were washed three times with Washing Buffer (20 mM 
HEPES pH 7.5, 50 mM NaCl, 1 mM DTT, 10% glycerol and 0.1% NP-40) at 4
o
C. Samples were 
eluted in 15 μl of 2x SDS sample buffer by incubation at 95oC for 5-10 min. One-third of the 
sample was loaded on a 15% SDS-PAGE gel for Western Blot analysis using anti-Ubc9 
antibodies.  Inputs were analyzed by Coomassie Blue staining.  
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RNA interference 
            HeLa cells were grown in a 6-well plate to 30-50% confluency and then transfected with 
Imp13 siRNA oligonucleotides using Oligofectamine (Invitrogen) according to the 
manufacturer’s instructions.  Control and Imp13 specific siRNA double stranded 
oligonucleotides were purchased from Dharmacon.  The sequences of siRNA oligos are listed in 
Appendix C.  72 h post-transfection, cells were lysed in 2x SDS sample buffer and analyzed by 
Western Blot using antibodies specific to Imp13, SUMO-1, SUMO-2/3, Tubulin, Ubc9 and 
Actin. 
To investigate the effect of Imp13 RNAi on Ubc9 nuclear localization, HeLa cells were 
transfected with GFP-Ubc9-WT using Lipofectamine-Plus reagents (Invitrogen) after 48 h of 
Imp13 RNAi and grown for additional 24 h.  The transfected cells were fixed with 3.5% 
paraformaldehyde for 30 min and directly analyzed by fluorescence microscopy. 
Western blot analysis 
            Proteins were first separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and then transferred to PVDF membrane for 2 h. After transfer, the membrane was blocked with 
5% milk in 1x TS buffer (50 mM Tris and 135mM NaCl) for 30 min at RT.  Membrane was 
incubated with the antibodies listed in Appendix D.  All primary antibodies were diluted in 1x 
PBS containing 2% BSA and 0.02% sodium azide. After incubation for 1 h at RT, the membrane 
was washed several times with 1x TS buffer containing 0.02% Tween-20 and then blotted with 
HRP-conjugated secondary antibody (GE Healthcare) (1:5000 dilution in 1xTS buffer with 5% 
milk) for 30 min at RT. After several washes, proteins were detected using ECL Prime (Western 
blotting detection reagent kit) (GE Healthcare). 
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Data quantification 
           For statistical analysis, fluorescent images were taken at 60x magnification.  The 
fluorescence intensities of Ubc9 in the nucleus and the cytoplasm were measured using Image J 
software (http://rsbweb.nih.gov/ij/). About 60 cells for each treatment were analyzed to calculate 
the nuclear/cytoplasmic ratio of Ubc9. 
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CHAPTER 3 - RESULTS 
Imp13 is required for efficient global SUMOylation 
           Although previous studies have shown that Imp13 can mediate the nuclear import of Ubc9 
using an in vitro nuclear import assays, little is known about the functional significance of Imp13 
in regulating Ubc9 nuclear localization in vivo.  Here we hypothesized that Imp13 is required for 
both Ubc9 nuclear localization and efficient SUMOylation in vivo.  To this hypothesis, Imp13 
was depleted in HeLa cells by RNA interference (RNAi).  Cells were transfected with either one 
of the three different siRNAs specific to Imp13 or control siRNAs.  After 72 h of transfection, 
cells were analyzed by immunoblotting using rabbit antibodies specific to Imp13.  As shown in 
Figure 6, Imp13 expression was efficiently inhibited in cells transfected with one of the three 
different Imp13-specific siRNAs when compared to cells transfected with control siRNAs. Next, 
we investigated if knockdown of Imp13 affects global SUMOylation.  Interestingly, we found a 
significant decrease of high molecular-weight SUMO-1 and SUMO-2/3 conjugates upon RNAi-
depletion of Imp13 as compared to control RNAi (Figure 6).  Furthermore, levels of Ubc9 
expression remained the same upon RNAi-depletion of Imp13 (Figure 6), indicating that the 
decrease of global SUMOylation upon Imp13 RNAi is not caused by reduced levels of Ubc9 
expression.  Immunoblotting analyses of whole cell lysates using anti-Tubulin and anti-Actin 
antibodies indicated that equal amounts of total proteins were present among different samples 
(Figure 6). 
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Figure 6. RNAi-mediated depletion of Imp13 leads to a decrease of global SUMOylation. 
HeLa cells were transfected with three different siRNAs specific to Imp13 and control siRNAs, 
respectively. After 72 h of transfection, cells were lysed and subjected to Western blot analysis 
with α-Imp13, α-SUMO-1, α-SUMO-2/3, α-Ubc9, α-Actin and α-Tubulin antibodies. 
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Imp13 is crucial for Ubc9 nuclear import in vivo 
The decrease of SUMOylation in cells with RNAi-depletion of Imp13 might be caused 
by a defect in Ubc9 nuclear localization.  Because Imp13 is a known nuclear import receptor for 
Ubc9 using in vitro nuclear import assays (Mingot et al., 2001), we hypothesized that Imp13 is 
required for the efficient nuclear import of Ubc9 in vivo.  To test this hypothesis, we depleted 
endogenous Imp13 in HeLa cells using siRNAs specific for Imp13. 48 h after RNAi-depletion of 
Imp13, cells were transfected with plasmids encoding GFP-Ubc9 for 24 h. Fluorescence 
microscopy showed that Ubc9 was predominantly concentrated in the nucleus with a very low 
level of cytoplasmic distribution in cells transfected with control siRNAs, whereas Imp13 
depletion caused a dramatic increase of the cytoplasmic distribution of Ubc9 (Figure 7A).  To 
accurately measure the effect of Imp13-depletion on Ubc9 distribution between the nucleus and 
the cytoplasm, we used Image J software to calculate the nuclear to cytoplasmic signal ratio 
(N/C) of GFP-tagged Ubc9 in cells transfected with Imp13-specific siRNAs and then compared 
to cells transfected with control siRNAs.  We found that around 82% of control-RNAi cells had 
an N/C ratio of larger than 4 (>4), whereas only 25% of Imp13-RNAi cells had the N/C ratio of 
>4 (Figure 7B).  This result clearly indicated that Imp13 depletion causes a great increase of 
cytoplasmic distribution of Ubc9 and that Imp13 is critical for Ubc9 nuclear localization in vivo.   
Interaction between Imp13 and Ubc9 is important for the nuclear localization of Ubc9  
To test if the interaction between Imp13 and Ubc9 is important for Ubc9 nuclear localization, the 
Ubc9-R17E mutant was generated with a defect in Imp13 binding (Grünwald and Bono, 2011).   
20 
 
 
 
 
 
Figure 7. Imp13 depletion causes an increase in the cytoplasmic distribution of Ubc9.  (A) 
HeLa cells were transfected with Imp13 siRNAs. After 48 h, cells were further transfected with 
plasmids encoding GFP-Ubc9-WT (wild-type). Fluorescence microscopy was used to analyze 
the result. White bars, 10 μm. (B) A histogram depicts the nuclear to cytoplasmic ratio of GFP-
Ubc9 signals in cells either transfected with the control or Imp13 siRNAs. The GFP-Ubc9 
signals were quantified using Image J software. The percentage of cells with relatively low 
nuclear to cytoplasmic ratios of GFP-Ubc9 signals was significantly increased in the Imp13-
RNAi cells when compared to the control-RNAi cells, indicating that Imp13 is crucial for the 
nuclear import of Ubc9 in vivo. 60 cells were analyzed for each sample. 
This R17E mutation on Ubc9 is known to disrupt its interaction with Imp13 using in vitro 
binding assays (Grünwald and Bono, 2011).  We performed a similar in vitro binding assay using 
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recombinant proteins.  The purified Ubc9-WT and Ubc9-R17E proteins were incubated with the 
glutathione beads containing immobilized GST-Imp13 and GST proteins, respectively.  Equal 
amounts of recombinant proteins were used for the in vitro binding assays as indicated by 
Commassie blue staining, whereas the GST proteins were used as a negative control (Figure 8A).  
The Ubc9-WT and Ubc9-R17E proteins bound to the glutathione beads were subjected to 
Western blot analysis using anti-Ubc9 antibodies (Figure 8B). The GST-Imp13 proteins 
efficiently pulled down Ubc9-WT, but not Ubc9-R17E (Figure 8B).  These results thereby 
confirm that the R17 residue on Ubc9 is crucial for its interaction with Imp13.  
           To further test whether Imp13 is important for Ubc9 nuclear localization, we compare the 
nuclear localization between GFP-Ubc9-WT and GFP-Ubc9-R17E. Plasmids encoding GFP-
Ubc9-WT or GFP-Ubc9-R17E were transiently transfected into HeLa cells for 24 h and the 
localization of GFP-Ubc9 was determined by fluorescence microscopy. We found that GFP-
Ubc9-WT was primarily localized to the nucleus, whereas GFP-Ubc9-R17E showed an increased 
cytoplasmic staining, indicating that Imp13 is an important import receptor for the nuclear 
accumulation of Ubc9 in mammalian cells (Figure 8C). By measuring the nuclear/cytoplasmic 
signal ratio of GFP-Ubc9-WT or GFP-Ubc9-R17E fusion proteins, we found that nearly all the 
cells expressing GFP-Ubc9-R17E have a low N/C ratio (1-2 or 2-3) of GFP signals compared to 
none of the cells of GFP-Ubc9-WT in this ratio (Figure 8D).  Hence, a defect in Ubc9 interaction 
with Imp13 resulted in a dramatic increase of cytoplasmic distribution of Ubc9. 
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Figure 8. The interaction between Imp13 and Ubc9 is crucial for Ubc9 nuclear 
accumulation. (A & B) In vitro binding assay.  (A) Equal amount of recombinant proteins as 
inputs were analyzed by Coomassie blue staining.  GST-Imp13 was incubated with Ubc9-WT or 
Ubc9-R17E. GST was used as a negative control.  (B) The pulled-down proteins were subjected 
to Western blot analysis using anti-Ubc9 antibody. (C) HeLa cells were transfected with 
plasmids encoding either GFP-Ubc9-WT or GFP-Ubc9-R17E with a defect in Imp13 binding. 
After 24 h of transfection, cells were analyzed using fluorescence microscopy. White bars, 10 
μm. (D) Histogram depicts the nuclear to cytoplasmic ratio of GFP-Ubc9 signals in 60 cells 
either transfected with Ubc9-WT or Ubc9-R17E. Cells were analyzed by Image J software.  All 
the cells expressing GFP-Ubc9-R17E have a low N/C ratio (1-2 or 2-3) of GFP signals, whereas 
no cells expressing GFP-Ubc9-WT have this low N/C ratio (1-2 or 2-3) of GFP signals  
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Overexpression of Imp13 enhances the nuclear accumulation of Ubc9 
            To further test the hypothesis that Imp13 is critical for the nuclear localization of Ubc9, 
HeLa cells were co-transfected with GFP-Ubc9-WT and HA-Imp13-WT, HA-Imp13-D426R or 
HA empty vector plasmids.  Cells transfected with GFP-Ubc9-WT plasmids and the 
corresponding empty vector were used as a negative control.  48 h post-transfection, 
immunofluorescence microscopy was performed using anti-HA antibodies. The Ubc9 nuclear 
distribution was enhanced in cells co-transfected with GFP-Ubc9-WT and HA-Imp13 when 
compared to cells co-transfected with GFP-Ubc9-WT and empty control vector (Figure 9A, 
Panel 1 and 2).  Furthermore, we co-transfected cells with plasmids encoding GFP-Ubc9-WT 
and HA-Imp13-D426R, the known Ubc9-interacting deficient mutant.  Interestingly, we 
observed that the cells co-expressing HA-Imp13-D426R and GFP-Ubc9-WT did not show an 
increase in Ubc9 nuclear distribution as compared to cells co-transfected with GFP-Ubc9-WT 
and HA-Imp13-WT or empty control constructs (Figure 9A).  Quantitative analysis was 
performed by calculating the percentage of cells with an indicated N/C ratio.  Overexpression of 
HA-Imp13-WT greatly increased the percentage of cells (92%) with the N/C ratio of >4 for 
GFP-Ubc9-WT signals, whereas only 38% of cells co-expressing HA-Imp13-D426R and GFP-
Ubc9 were found with this high N/C ratio (>4) for GFP-Ubc9-WT signals (Figure 9B).    
           We also performed a similar experiment by co-transfecting HeLa cells with GFP-Ubc9-
R17E and HA-Imp13 or empty vector plasmids. Cells that co-expressed HA-Imp13 and GFP-
Ubc9-R17E only slightly increased the nuclear accumulation of Ubc9 as compared to cells co-
transfected with GFP-Ubc9-R17E and control plasmids (Figure 10A). However, this increase of 
Ubc9 nuclear distribution in these cells was much lower than that in cells co-transfected with  
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Figure 9. Overexpression of Imp13 greatly increases the nuclear accumulation of Ubc9. 
(A) HeLa cells were co-transfected with GFP-Ubc9-WT and empty control vector, HA-Imp13-
WT or HA-Imp13-D426R plasmids with a defect in Ubc9 binding. 48 h post-transfection, cells 
were subjected to immunofluorescence microscopy using anti-HA antibodies. White bars, 10 
μm. (B) Histogram depicts the nuclear to cytoplasmic ratio of GFP-Ubc9 signals in transfected 
cells. 60 cells were analyzed for each sample. 
 
HA-Imp13 and GFP-Ubc9-WT constructs (Figures 9A and 10A). Quantitative analysis indicated 
that cells co-transfected with HA-Imp13 and GFP-Ubc9-R17E only modestly increased the 
percentage of cells with a high N/C ratio of GFP-UBC9-R17E when compared to cells co-
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transfected with GFP-Ubc9-R17E and empty vector plasmids.  These results further 
demonstrated that Imp13 can efficiently transport Ubc9 from the cytoplasm to the nucleus and 
that the Imp13-Ubc9 interaction is critical for the nuclear accumulation of Ubc9 in vivo.          
 
               
 
Figure 10. Overexpression of Imp13 only modestly increases the nuclear accumulation of 
Ubc9-R17E mutant.  (A) HeLa cells were co-transfected with GFP-Ubc9-R17E and empty 
control vector or HA-Imp13-WT plasmids. 48 h post-transfection, cells were analyzed by 
immunofluorescence microscopy. White bars, 5μm. (B) Histogram shows the nuclear to 
cytoplasmic ratio of GFP-Ubc9-R17E signals in transfected cells. 60 cells were analyzed for 
each sample.  
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Non-covalent interaction of Ubc9 and SUMO is necessary for nuclear localization of Ubc9 
 
 
Figure 11. The SUMO-binding activity of Ubc9 is critical for its accumulation in the 
nucleus.  HeLa cells were transfected with plasmids encoding either GFP-Ubc9-WT or one of 
the SUMO-binding deficient mutants of Ubc9, including GFP-Ubc9-R17E, GFP-Ubc9-R13A 
and GFP-Ubc9-H20D. After 24h, cells were fixed with 3.5% paraformaldehyde and then 
analyzed by fluorescence microscopy. White bars, 10 μm. 
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           The predominant nuclear distribution of both SUMO-1 and SUMO-2/3 leads us to explore 
whether the interaction between Ubc9 and SUMOs also contributes to the nuclear localization of 
Ubc9.  It has been shown previously that several amino acid residues on Ubc9 are essential for 
its interaction with SUMOs.  These known Ubc9 mutants, including R13A, R17E and H20D, 
have a defect in forming the Ubc9-SUMO complex (Capili and Lima, 2007; Knipscheer et al., 
2007).   Based on these findings, we tested whether these Ubc9 mutants with a defect in their 
interaction with SUMO exhibit a decreased nuclear distribution along with an increase in their 
cytoplasmic localization. 
             HeLa cells were transfected with GFP-Ubc9-WT or one of the SUMO-binding mutants 
of Ubc9, including GFP-Ubc9-R17E, GFP-Ubc9-R13A and GFP-Ubc9-H20D. 24 h post-
transfection, cells were fixed with 3.5% para-formaldehyde and analyzed by fluorescence 
microscopy. GFP-Ubc9-R17E, GFP-Ubc9-R13A and GFP-Ubc9-H20D mutants exhibited a 
decreased nuclear accumulation and also an increased cytoplasmic distribution when compared 
to GFP-Ubc9-WT. This result indicated that the Ubc9-SUMO interaction is also important for 
Ubc9 nuclear localization. 
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CHAPTER 4 - DISCUSSION 
            SUMOylation is catalyzed by a cascade of enzymes including a SUMO-E1 activating 
enzyme (SAE1/SAE2), a SUMO-E2 conjugating enzyme (Ubc9) and several E3 ligases. SUMO-
E1, SUMO-E2 and SUMOs are known to be majorly localized in the nucleus (Azuma et al., 
2001; Saitoh et al., 2001; Zhang et al., 2008). It has been hypothesized that SUMOylation occur 
majorly in the nucleus since most of the SUMOylated proteins along with the SUMOylation 
machinery are nuclear (Rodriguez et al., 2001). Therefore, it is important to understand the 
mechanisms regulating the nuclear localization of these enzymes. Studies have shown that 
SUMO-E1 enzyme is imported to the nucleus by Importinα/β (Moutty et al., 2011). In our study, 
we elucidated the mechanisms responsible for the nuclear localization of Ubc9 and found that 
nuclear localization of Ubc9 is important for efficient SUMOylation.  A study by Mingot et al., 
(2001) has shown that Imp13 can mediate the nuclear import of Ubc9 in vitro.  Based on this 
study, we explored whether Imp13 is critical for Ubc9 nuclear localization in mammalian cells. 
Consistent with our hypothesis, we demonstrated that inhibition of Imp13 causes a significant 
reduction of Ubc9 nuclear accumulation and also a dramatic decrease of SUMO-1 and SUMO-
2/3 modification in vivo (Figure 6 and 7).  
         Structural studies have shown the R17 residue of Ubc9 is critical for its interaction with 
Imp13 in vitro (Grunwald and Bono, 2011).  Our immunofluorescence microscopy revealed an 
increase of the cytoplasmic distribution of GFP-Ubc9-R17E as compared to GFP-Ubc9-WT.  A 
recent study has also shown that GFP-Ubc9-R17E has an increased cytoplasmic distribution as 
compared to GFP-Ubc9-WT with a predominant nuclear localization (Grunwald et al., 2013).  
To further test the function significance of the Imp13-Ubc9 interaction in control of Ubc9 
nuclear localization, we compared the capacities of Imp13-WT and Imp13-D426R mutant with a 
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defect in Ubc9 interaction on enhancing the nuclear accumulation of GFP-Ubc9-WT.  We found 
that overexpression of HA-Imp13-WT greatly increased the nuclear accumulation of GFP-Ubc9-
WT with 92% of the cells with a high N/C ratio of >4 but only modestly elevated the nuclear 
distribution of GFP-Ubc9-R17E with 25% of the cells having a N/C ratio of >4.  Consistent with 
the above result, overexpression of Imp13-D426R mutant had very little effect on the nuclear 
accumulation of GFP-Ubc9-WT (Figure 9B). These results clearly indicate that interaction 
between Imp13 and Ubc9 is important for nuclear accumulation of Ubc9. 
We also test if the SUMO-binding activity of Ubc9 plays a role in Ubc9 nuclear 
accumulation. This idea was supported by the findings that SUMO and Ubc9 can form a 
complex in vitro and that this complex formation is destabilized using Ubc9 mutants (Ubc9-
R17E, Ubc9-R13A and Ubc9-H20D) with a defect in their SUMO binding (Capili and Lima, 
2007; Knipscheer et al., 2007). Consistent with our hypothesis, we found that these Ubc9 
mutants displayed an increased cytoplasmic distribution when compared to Ubc9-WT. 
Interestingly, Ubc9-R17E showed a higher cytoplasmic distribution than Ubc9-R13A and Ubc9-
H20D. Previous studies have shown that the R17 residue of Ubc9 is known to be important for 
its binding to both Imp13 and SUMO (Grunwald and Bono, 2010; Capili and Lima, 2007). 
Clearly, these results have demonstrated that both Imp13-mediate nuclear import of Ubc9 and 
the SUMO-binding activity of Ubc9 are important for Ubc9 nuclear localization. The Ubc9-
SUMO interaction may function as an anchorage to retain Ubc9 at the nucleus. 
Based on our findings, we propose a model in which two mechanisms are responsible for 
the nuclear localization of Ubc9 and efficient SUMOylation (Figure 12).  Imp13 binds to the 
Ubc9 in the cytoplasm and translocates it to the nucleus where Ubc9 is then released from the 
Imp13-Ubc9 complex upon RanGTP binding. Ubc9 is the sole SUMO-E2 conjugating enzyme 
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participating in the SUMO-conjugation process. Upon depletion of Imp13 in the cells, Ubc9 
nuclear import is blocked, leading to a decrease of the global SUMOylation.  Notably, the Ubc9-
SUMO interaction can occur between Ubc9 and free-SUMOs or SUMO-conjugates. In our 
study, we described three critical residues of Ubc9 (R17, R13 and H20) that are important for its 
SUMO-binding as well as its nuclear localization.  
             We are currently testing whether another possible mechanism is important for Ubc9 
nuclear accumulation. As previously discussed, during the SUMO conjugation pathway, Ubc9 
recognizes the SUMOylation consensus site of the target for SUMO-conjugation. Furthermore, 
structural studies have shown residues on Ubc9 which are crucial for its recognition of the 
SUMOylation consensus motif on the target proteins (Reverter and Lima, 2005; Villamor et al., 
2002). SUMO-conjugation assay using Ubc9 mutants with a defect in binding to the SUMO 
consensus motif exhibited reduced SUMO conjugation for the substrates including RanGAP1, 
p53 and IκBα (Villamor et al., 2002). This evidence provides a clue that Ubc9 interaction with 
the SUMO consensus sequence might also regulate the nuclear localization of Ubc9. To address 
this question, we will generate a series of Ubc9 mutants with a defect in interaction with the 
SUMOylation consensus site and investigate whether this interaction is important for Ubc9 
nuclear localization. 
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Figure 12. A model illustrates the mechanisms in regulating Ubc9 nuclear localization. 
Imp13 mediates the nuclear import of Ubc9, which is important for efficient global 
SUMOylation.  As the sole E2 conjugating enzyme, Ubc9 is essential for SUMO conjugation. 
We found that both Imp13-mediated nuclear import of Ubc9 and the SUMO binding activity of 
Ubc9 are essential for Ubc9 accumulation in the nucleus. The red hinge on Ubc9 denotes its 
SUMO binding sites. 
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Appendix A: Primers used for subclonings 
Primer name Primer 
GFP-Imp13-forward GCCTCGAGCTATGGAGCGGCGG 
GFP-Imp13-reverse CGGGATCCTCAGTAGTCAGCTGTGTAAT 
GST-Imp13-forward GCGGATCCATGGAGCGGCGGG 
GST-Imp13-reverse CGCTCGAGCACCACATCAGAATAG 
GFP-Ubc9-forward GGAATTCTATGTCGGGGATCGC 
GFP-Ubc9-reverse CGGGATCCTTATGAGGGCGC 
GST-Ubc9-forward GCGGATCCATGTCGGGGATC 
GST-Ubc9-reverse CGCTCGAGTTATGAGGGCGC 
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Appendix B: Mutagenesis primers 
Primer name Primer 
Ubc9-R17E-forward CAGGAGAGGAAAGCATGGGAGAAAGACCACCC
ATTT 
Ubc9-R17E-reverse AAATGGGTGGTCTTTCTCCCATGCTTTCCTCTCC
TG 
Ubc9-R13A-forward CTCGCCCAGGAGGCGAAAGCATGGAGG 
Ubc9-R13A-reverse CCTCCATGCTTTCGCCTCCTGGGCGAG 
Ubc9-H20D-forward GCATGGAGGAAAGACGACCCATTTGGTTTC 
Ubc9-H20D-reverse GAAACCAAATGGGTCGTCTTTCCTCCATGC 
Imp13-D426R-forward CGTATCTACAGGGTGCGCATCTCAGACACACTC 
Imp13-D426R-reverse GAGTGTGTCTGAGATGCGCACCCTGTAGATACG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
 
 
Appendix C: siRNA oligos 
siRNA oligo name Primer 
Imp13 1588-forward  UGCCAUCUCACAGCCUGA 
Imp13 1588-reverse AUCAGGCUGUGAGAUGGCA 
Imp13 1014-forward CAUGAUUAUGUUCUGCACA 
Imp13 1014-reverse UGUGCAGAACAUAAUCAUG 
Imp13 114-forward CAUUGAGAAUAAGAACCUG 
Imp13 114-reverse CAGGUUCUUAUUCUCAAUG 
Control-forward UUCUCCGAACGUGUCACGU 
Control-reverse ACGUGACACGUUCGGAGAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
 
 
Appendix D: Antibodies 
Antibodies Species Sources Dilution 
SUMO-1 (21C7) Mouse Invitrogen 1:1000 
SUMO-2/3 (8A2) Mouse Abcam 1:800 
Tubulin Mouse Sigma 1:5000 
Ubc9 Rabbit Genetex 1:5000 
Actin Mouse Genscript 1:3000 
Importin13 Rabbit Dr.Feige Kaplan 1:500 
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           The covalent and reversible conjugation of small ubiquitin-like modifier (SUMO) proteins 
to hundreds of different cellular proteins is catalyzed by a cascade of enzymes including an E1-
activating enzyme (SAE1/SAE2), an E2-conjugating enzyme (Ubc9) and multiple E3 ligases.  
As the only E2 enzyme for SUMO-conjugation, Ubc9 localizes mainly in the nucleus and plays 
an essential role in regulation of many cellular processes including cell cycle progression 
through mitosis, cell migration, genome stability, stress response, transcription, and nuclear 
transport in eukaryotic cells. It is hypothesized that the nuclear localization of Ubc9 is required 
for efficient sumoylation inside the nucleus because both the sole SUMO E1 enzyme and 
SUMO-conjugates are mainly in the nucleus. However, we still have a poor understanding of 
how Ubc9 is accumulated in the nucleus. Although the nuclear import receptor Importin 13 
(Imp13) can mediate the nuclear import of Ubc9 using in vitro nuclear import assays, little is 
known about how Ubc9 nuclear localization is regulated in vivo. Here, we hypothesize that 
Imp13 is the major nuclear import receptor for Ubc9 and thus required for efficient global 
sumoylation in vivo. Consistent with this hypothesis, we found that knockdown of Imp13 by 
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RNA interference (RNAi) causes a decrease of global sumoylation and also an increased 
cytoplasmic distribution of Ubc9.  Furthermore, the Ubc9 mutant (R17E) with a defect in Imp13-
interaction showed a significant increase of cytoplasmic distribution when compared to Ubc9 
wild-type (WT).  Moreover, overexpression of Imp13 greatly enhanced the nuclear localization 
of Ubc9-WT but not Ubc9-R17E mutant, whereas overexpression of Imp13 mutant (D426R) 
with a defect in Ubc9 binding could not promote the nuclear accumulation of Ubc9-WT.  Lastly, 
we demonstrated that the Ubc9 mutants (R17E, R13A and H20D) with a defect in SUMO-
binding have an elevated cytoplasmic distribution when compared to Ubc9-WT, suggesting that 
the non-covalent interaction between Ubc9 and SUMO is also important for Ubc9 nuclear 
accumulation.  Hence, our results support a model that both Imp13-mediated nuclear import and 
the SUMO-binding activity of Ubc9 are critical for Ubc9 nuclear localization and efficient global 
sumoylation in mammalian cells. 
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